Cargando…

Aptamer-based applications for cardiovascular disease

Cardiovascular disease (especially atherosclerosis) is a major cause of death worldwide, and novel diagnostic tools and treatments for this disease are urgently needed. Aptamers are single-stranded oligonucleotides that specifically recognize and bind to the targets by forming unique structures in v...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xinyuan, Ma, Yue, Xie, Yuquan, Pu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606242/
https://www.ncbi.nlm.nih.gov/pubmed/36312558
http://dx.doi.org/10.3389/fbioe.2022.1002285
_version_ 1784818250208509952
author Chen, Xinyuan
Ma, Yue
Xie, Yuquan
Pu, Jun
author_facet Chen, Xinyuan
Ma, Yue
Xie, Yuquan
Pu, Jun
author_sort Chen, Xinyuan
collection PubMed
description Cardiovascular disease (especially atherosclerosis) is a major cause of death worldwide, and novel diagnostic tools and treatments for this disease are urgently needed. Aptamers are single-stranded oligonucleotides that specifically recognize and bind to the targets by forming unique structures in vivo, enabling them to rival antibodies in cardiac applications. Chemically synthesized aptamers can be readily modified in a site-specific way, so they have been engineered in the diagnosis of cardiac diseases and anti-thrombosis therapeutics. Von Willebrand Factor plays a unique role in the formation of thrombus, and as an aptamer targeting molecule, has shown initial success in antithrombotic treatment. A combination of von Willebrand Factor and nucleic acid aptamers can effectively inhibit the progression of blood clots, presenting a positive diagnosis and therapeutic effect, as well as laying a novel theory and strategy to improve biocompatibility paclitaxel drug balloon or implanted stent in the future. This review summarizes aptamer-based applications in cardiovascular disease, including biomarker discovery and future management strategy. Although relevant applications are relatively new, the significant advancements achieved have demonstrated that aptamers can be promising agents to realize the integration of diagnosis and therapy in cardiac research.
format Online
Article
Text
id pubmed-9606242
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96062422022-10-28 Aptamer-based applications for cardiovascular disease Chen, Xinyuan Ma, Yue Xie, Yuquan Pu, Jun Front Bioeng Biotechnol Bioengineering and Biotechnology Cardiovascular disease (especially atherosclerosis) is a major cause of death worldwide, and novel diagnostic tools and treatments for this disease are urgently needed. Aptamers are single-stranded oligonucleotides that specifically recognize and bind to the targets by forming unique structures in vivo, enabling them to rival antibodies in cardiac applications. Chemically synthesized aptamers can be readily modified in a site-specific way, so they have been engineered in the diagnosis of cardiac diseases and anti-thrombosis therapeutics. Von Willebrand Factor plays a unique role in the formation of thrombus, and as an aptamer targeting molecule, has shown initial success in antithrombotic treatment. A combination of von Willebrand Factor and nucleic acid aptamers can effectively inhibit the progression of blood clots, presenting a positive diagnosis and therapeutic effect, as well as laying a novel theory and strategy to improve biocompatibility paclitaxel drug balloon or implanted stent in the future. This review summarizes aptamer-based applications in cardiovascular disease, including biomarker discovery and future management strategy. Although relevant applications are relatively new, the significant advancements achieved have demonstrated that aptamers can be promising agents to realize the integration of diagnosis and therapy in cardiac research. Frontiers Media S.A. 2022-10-13 /pmc/articles/PMC9606242/ /pubmed/36312558 http://dx.doi.org/10.3389/fbioe.2022.1002285 Text en Copyright © 2022 Chen, Ma, Xie and Pu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Chen, Xinyuan
Ma, Yue
Xie, Yuquan
Pu, Jun
Aptamer-based applications for cardiovascular disease
title Aptamer-based applications for cardiovascular disease
title_full Aptamer-based applications for cardiovascular disease
title_fullStr Aptamer-based applications for cardiovascular disease
title_full_unstemmed Aptamer-based applications for cardiovascular disease
title_short Aptamer-based applications for cardiovascular disease
title_sort aptamer-based applications for cardiovascular disease
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606242/
https://www.ncbi.nlm.nih.gov/pubmed/36312558
http://dx.doi.org/10.3389/fbioe.2022.1002285
work_keys_str_mv AT chenxinyuan aptamerbasedapplicationsforcardiovasculardisease
AT mayue aptamerbasedapplicationsforcardiovasculardisease
AT xieyuquan aptamerbasedapplicationsforcardiovasculardisease
AT pujun aptamerbasedapplicationsforcardiovasculardisease